Publicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (22)

2023

  1. Physicians’ attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study

    Clinical and Translational Oncology, Vol. 25, Núm. 1, pp. 151-159

2021

  1. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

    Breast Cancer Research and Treatment, Vol. 178, Núm. 2, pp. 251-261

  2. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

2018

  1. Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143

2015

  1. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

    Annals of Oncology, Vol. 26, Núm. 7, pp. 1280-1291

2013

  1. An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer

    Breast, Vol. 22, Núm. 5, pp. 974-979

2012

  1. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer

    Breast Cancer Research, Vol. 14, Núm. 5

  2. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

    Oncologist, Vol. 17, Núm. 6, pp. 766-774

  3. Progress against solid tumors in danger: The metastatic breast cancer example

    Journal of Clinical Oncology

2011

  1. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer

    JAMA - Journal of the American Medical Association, Vol. 305, Núm. 18, pp. 1873-1881

  2. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

    Clinical Proteomics, Vol. 8, Núm. 1

  3. Prognostic impact of phosphorylated HER-2 in HER-2 + primary breast cancer

    Oncologist, Vol. 16, Núm. 7, pp. 956-965

2010

  1. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer

    Clinical Cancer Research, Vol. 16, Núm. 21, pp. 5351-5361

  2. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

    Breast Cancer Research, Vol. 12, Núm. 3

2009

  1. AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

    Cancer Cell, Vol. 16, Núm. 1, pp. 21-32

  2. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

    Cancer Research, Vol. 69, Núm. 10, pp. 4116-4124

  3. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer

    Clinical Cancer Research, Vol. 15, Núm. 11, pp. 3654-3662

2008

  1. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

    Cancer Research, Vol. 68, Núm. 15, pp. 6084-6091

2007

  1. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 23, pp. 3399-3406